ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 7997444#:
USA: +1 8338186807 | United-Kingdom: +44 02031070289 | |||||
Switzerland: +080 0836508 | Germany: +49 06922224728 | |||||
France: +33 0176748988 | Belgium: +32 024003547 | |||||
Sweden: +46 0856619361 | Finland: +358 0972519310 | |||||
Netherlands: +31 0207075547 | Spain: +34 914142503 | |||||
The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/qa7wj9by
An archived replay of the call will be available for 7 days by dialing
(US &
An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 trial in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational
manufacturing site in
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in
View source version on businesswire.com: http://www.businesswire.com/news/home/20180305006083/en/
Source:
ERYTECH
Naomi Eichenbaum
Director of Investor
Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
The
Ruth Group
Lee Roth
Investor relations
Kirsten
Thomas
Media relations
+1 646 536 7012
lroth@theruthgroup.com
+1
508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien
Perez
Investor relations
Nicolas Merigeau
Media
relations
+33 1 44 71 98 52
erytech@newcap.eu